Baker D - Search Results

1

Simvastatin in patients with progressive multiple sclerosis.

Giovannoni G, Baker D, Schmierer K. Giovannoni G, et al. Among authors: baker d. Lancet. 2014 Sep 13;384(9947):952. doi: 10.1016/S0140-6736(14)61621-4. Lancet. 2014. PMID: 25220965 No abstract available.

2

Mifepristone or inhibition of 11beta-hydroxylase activity potentiates the sedating effects of the cannabinoid receptor-1 agonist Delta(9)-tetrahydrocannabinol in mice.

Pryce G, Giovannoni G, Baker D. Pryce G, et al. Among authors: baker d. Neurosci Lett. 2003 May 1;341(2):164-6. doi: 10.1016/s0304-3940(03)00159-9. Neurosci Lett. 2003. PMID: 12686391

3

Quantification of neurodegeneration by measurement of brain-specific proteins.

Petzold A, Baker D, Pryce G, Keir G, Thompson EJ, Giovannoni G. Petzold A, et al. Among authors: baker d. J Neuroimmunol. 2003 May;138(1-2):45-8. doi: 10.1016/s0165-5728(03)00092-4. J Neuroimmunol. 2003. PMID: 12742652 Free article.

4

The therapeutic potential of cannabis.

Baker D, Pryce G, Giovannoni G, Thompson AJ. Baker D, et al. Lancet Neurol. 2003 May;2(5):291-8. doi: 10.1016/s1474-4422(03)00381-8. Lancet Neurol. 2003. PMID: 12849183 Review.

5

Potential of statins for the treatment of multiple sclerosis.

Baker D, Adamson P, Greenwood J. Baker D, et al. Lancet Neurol. 2003 Jan;2(1):9-10. doi: 10.1016/s1474-4422(03)00256-4. Lancet Neurol. 2003. PMID: 12849290 No abstract available.

6

Inflammatory disorders of the central nervous system.

Giovannoni G, Baker D. Giovannoni G, et al. Among authors: baker d. Curr Opin Neurol. 2003 Jun;16(3):347-50. doi: 10.1097/01.wco.0000073936.19076.9c. Curr Opin Neurol. 2003. PMID: 12858072 Review. No abstract available.

7

Cannabinoids inhibit neurodegeneration in models of multiple sclerosis.

Pryce G, Ahmed Z, Hankey DJ, Jackson SJ, Croxford JL, Pocock JM, Ledent C, Petzold A, Thompson AJ, Giovannoni G, Cuzner ML, Baker D. Pryce G, et al. Among authors: baker d. Brain. 2003 Oct;126(Pt 10):2191-202. doi: 10.1093/brain/awg224. Epub 2003 Jul 22. Brain. 2003. PMID: 12876144

8

Autoimmune tolerance eliminates relapses but fails to halt progression in a model of multiple sclerosis.

Pryce G, O'Neill JK, Croxford JL, Amor S, Hankey DJ, East E, Giovannoni G, Baker D. Pryce G, et al. Among authors: baker d. J Neuroimmunol. 2005 Aug;165(1-2):41-52. doi: 10.1016/j.jneuroim.2005.04.009. J Neuroimmunol. 2005. PMID: 15939483

9

Direct suppression of CNS autoimmune inflammation via the cannabinoid receptor CB1 on neurons and CB2 on autoreactive T cells.

Maresz K, Pryce G, Ponomarev ED, Marsicano G, Croxford JL, Shriver LP, Ledent C, Cheng X, Carrier EJ, Mann MK, Giovannoni G, Pertwee RG, Yamamura T, Buckley NE, Hillard CJ, Lutz B, Baker D, Dittel BN. Maresz K, et al. Among authors: baker d. Nat Med. 2007 Apr;13(4):492-7. doi: 10.1038/nm1561. Epub 2007 Apr 1. Nat Med. 2007. PMID: 17401376

10

Cannabinoid-mediated neuroprotection, not immunosuppression, may be more relevant to multiple sclerosis.

Croxford JL, Pryce G, Jackson SJ, Ledent C, Giovannoni G, Pertwee RG, Yamamura T, Baker D. Croxford JL, et al. Among authors: baker d. J Neuroimmunol. 2008 Jan;193(1-2):120-9. doi: 10.1016/j.jneuroim.2007.10.024. Epub 2007 Nov 26. J Neuroimmunol. 2008. PMID: 18037503

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

5,776 results

Search Page

Filters